Evidence-Based Clinical Updates in the Treatment of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
For information about AMA PRA Category 2 CreditTM, you may consult page 10 of the AMA’s booklet “The Physicians Recognition Award and credit system: Information for accredited providers and physicians – 2010 Revision” found here.
The aim of the project is to ensure hematology care teams participating in new value-based reimbursement models have an accurate understanding of the evidence and roles of new therapies for relapsed/refractory Chronic Lymphocytic Leukemia (CLL), as well as best supportive care practices to promote therapy adherence, quality of life, and reduction of unanticipated healthcare utilization (specifically ED visits and hospitalizations).
- Re-evaluate current treatment approaches for patients with relapsed/refractory CLL in light of newly emerging clinical data
- Personalize the supportive care strategies for patients with relapsed/refractory CLL based on selected treatment and relevant clinical and patient-reported symptom experience
- Evaluate population level trends regarding symptom experiences and the effectiveness of supportive care strategies for CLL in the relapsed/refractory settings to inform practice and determine future research questions
DOWNLOAD PDFDownload Activity
VIEW ON SLIDESHARE
This activity is supported by an independent educational grant from Genentech BioOncology. Activity ID: G-411